Adult patients with acute lymphoblastic leukaemia who experience relapsed or refractory disease have a poor prognosis. Inotuzumab ozogamicin (InO), an anti-CD22 antibody drug conjugate, could be a new option for treatment in these patients. At the EHA 2015 in Vienna, Dr. Daniel DeAngelo (Dana-Farber Cancer Institute, Boston) presented data from a phase III study comparing InO with standard of care (SOC).
(BELG J HEMATOL 2015;6(3):91–2)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
